^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    B7-H3 inhibitor

    Related drugs:
    1m
    GPC3 chimeric antigen receptor (CAR)-NK cells combined with Enoblituzumab enhance the anti-tumor efficacy against hepatocellular carcinoma. (PubMed, Biochem Biophys Res Commun)
    Our findings demonstrate that dual targeting of GPC3 and B7H3 effectively enhances NK cell-mediated antitumor activity. This strategy leverages both CAR-mediated specificity and NK cell-intrinsic mechanisms, providing a strong rationale for developing dual-target immunotherapies to improve outcomes in HCC patients.
    Journal • IO biomarker
    |
    IFNG (Interferon, gamma) • CD276 (CD276 Molecule) • GPC3 (Glypican 3) • LAMP1 (Lysosomal Associated Membrane Protein 1)
    |
    enoblituzumab (MGA271)
    3ms
    A Phase I Clinical Study of HLX316 in Participants With Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=41, Recruiting, Shanghai Henlius Biotech | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    CD276 (CD276 Molecule) • MUC16 (Mucin 16, Cell Surface Associated)
    3ms
    Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=90, Not yet recruiting, Xencor, Inc.
    New P1 trial
    |
    CLDN6 (Claudin 6)
    3ms
    BActinium-1: A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=138, Recruiting, Aktis Oncology, Inc.
    New P1 trial
    3ms
    Engineering functionality-optimized fully human B7-H3 CAR T cells for enhanced solid tumor therapy. (PubMed, Cell Rep Med)
    In pancreatic cancer, neuroblastoma, and glioblastoma xenograft models, CAR T cells incorporating the lead human binder Y111 are well tolerated and demonstrate superior antitumor activity compared with 376.96- and MGA271-based CARs. Y111 CAR treatment induces complete responses, tumor rejection, and significant survival benefits, identifying Y111 as a promising fully human B7-H3 CAR for solid tumors.
    Journal
    |
    CD276 (CD276 Molecule)
    |
    enoblituzumab (MGA271)
    4ms
    GTB-5550 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=175, Recruiting, Masonic Cancer Center, University of Minnesota
    New P1 trial • First-in-human
    |
    GTB-5550
    4ms
    A Phase I Clinical Study of HLX316 in Participants With Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=41, Not yet recruiting, Shanghai Henlius Biotech
    New P1 trial • First-in-human
    |
    CD276 (CD276 Molecule) • MUC16 (Mucin 16, Cell Surface Associated)
    6ms
    B7-H3-mediated cis-inhibition of EGFR by a tumor-selective bispecific antibody enhances anti-tumor efficacy and minimizes toxicities. (PubMed, Nat Commun)
    Toxicological evaluations in non-human primates reveals a favorable safety profile, with no EGFR-related adverse effects observed at doses up to 120 mg/kg over 4 weeks. Supported by these preclinical findings, IBI334 has advanced to a phase 1 clinical trial (NCT05774873) for advanced/metastatic solid tumors.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • CD276 (CD276 Molecule)
    |
    EGFR positive
    |
    IBI-334
    6ms
    pH/ROS-Responsive Injectable Hydrogel Co-Loaded with B7-H3 Blocker and NETs Suppressor Boosts OSCC Synergistic Immunotherapy. (PubMed, Adv Sci (Weinh))
    This study presents an injectable pH/ROS-dual-responsive hydrogel co-loaded with enoblituzumab (B7-H3 blocker) and Cl-amidine (NETs suppressor)...The hydrogel exhibits excellent biocompatibility without systemic toxicity. This TME-responsive combination strategy offers a promising approach to enhance immunotherapy efficacy and overcome immune resistance in OSCC.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD276 (CD276 Molecule) • CD4 (CD4 Molecule)
    |
    enoblituzumab (MGA271)
    6ms
    131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (clinicaltrials.gov)
    P2, N=62, Active, not recruiting, Pediatric Brain Tumor Consortium | Trial completion date: Oct 2030 --> Sep 2027 | Trial primary completion date: Oct 2029 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    CD276 (CD276 Molecule)
    |
    Avastin (bevacizumab) • temozolomide • irinotecan • dexamethasone injection • Omblastys (131I-omburtamab) • ondansetron intravenous
    7ms
    Engineering Functionality Optimized fully human B7-H3 CAR T Cells for Enhanced Solid Tumor Therapy. (PubMed, bioRxiv)
    In pancreatic cancer, neuroblastoma, and glioblastoma xenograft models, CAR T cells incorporating the lead human binder Y111 were well tolerated and demonstrated superior antitumor activity compared with 376.96- and MGA271-based CARs. Y111 CAR treatment induced complete responses, tumor rejection, and significant survival benefits, identifying Y111 as a promising fully human B7-H3 CAR for solid tumors.
    Journal
    |
    CD276 (CD276 Molecule)
    |
    enoblituzumab (MGA271)
    7ms
    177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=61, Recruiting, Radiopharm Theranostics, Ltd | Not yet recruiting --> Recruiting | Initiation date: Nov 2025 --> Feb 2026
    Enrollment open • Trial initiation date